2026-04-28

India’s rare disease ecosystem is at a pivotal inflection point. While scientific advancement has made effective therapies increasingly available, the real challenge is no longer innovation—it is access.

In conditions such as Wilson’s Disease (WD), where timely intervention can significantly alter disease progression, the gap between diagnosis and consistent treatment remains a critical concern. The conversation is therefore shifting from what therapies exist to how effectively these reach the patients who need them.

A Treatable Disease Still Facing Systemic Barriers
WD, a genetic disorder of copper metabolism, is clinically well understood and, importantly, treatable. Yet, in India, systemic challenges continue to delay optimal care.

Globally, the prevalence of WD is estimated at approximately one in 30,000 individuals, with a carrier frequency of around one in 90. However, emerging genetic data suggest that the true prevalence may be significantly higher, potentially as common as one in 7,000 in certain populations, largely due to underdiagnosis.

In India, precise epidemiological data remain limited. However, hospital-based studies indicate a prevalence ranging from one in 20,000 to one in 30,000, with certain regions demonstrating higher incidence linked to genetic factors and consanguinity.

Despite being treatable, diagnosis is often delayed frequently by two to four years due to limited awareness, variability in clinical suspicion and uneven access to specialised diagnostic infrastructure. By the time many patients enter the treatment pathway, disease progression has already impacted hepatic or neurological function.

This underscores a critical reality within rare disease management: the burden of disease is not only defined by prevalence, but by the gap between detection and intervention. Clinical understanding alone is insufficient without timely diagnosis and reliable access to appropriate treatment.

Chelation Therapy: From Standard of Care to Evolving Preference
Long-term disease management in WD depends on sustained copper control, primarily through chelation therapy and zinc supplementation. Chelating agents remain the cornerstone of treatment, enabling the removal of excess copper and stabilisation of disease progression.

Historically, D-penicillamine has been widely adopted as a first-line therapy. However, its clinical utility has been tempered by well-documented challenges related to tolerability and adverse effects, which can impact long-term adherence.

This has driven a gradual but meaningful shift in clinical preference towards alternative agents such as Trientine, particularly in patients who are intolerant to first-line therapy or require improved safety profiles for sustained treatment.

Improved Availability and Continuity of Care
A significant development in recent years has been the availability of Trientine in India, marking an important step forward in rare disease treatment access. Where access to certain advanced therapies was previously constrained by complex procurement pathways, clinicians can now prescribe Trientine within India through appropriate channels, based on clinical need.

This evolution is more than logistical. It has direct implications for patient care:
• Earlier initiation of appropriate therapy
• Greater treatment adherence due to improved tolerability
• Reduced interruptions in long-term disease management
• Enhanced physician confidence in therapy selection

In chronic conditions such as WD, where treatment is lifelong, consistency of access is as critical as efficacy itself.

The Role of Industry in Strengthening Access Frameworks
The role of industry in this transition is both strategic and enabling. Trientine formulations, such as Triokris, are manufactured in US Food and Drug Administration (FDA)-compliant facilities. This represents the convergence of global quality standards with local accessibility. By ensuring that advanced therapies are not only developed, but also made consistently available within India, such models address a long-standing gap between innovation and delivery.

This approach reflects a broader shift in the pharmaceutical landscape, where success is increasingly defined not just by product development, but by the ability to integrate access into the therapy lifecycle.

Rare Disease Care in India: From Awareness to Access
India’s rare disease framework is steadily evolving. While awareness initiatives have laid the groundwork, the next phase of progress will depend on strengthening diagnostic timelines, treatment accessibility, physician education andlong-term care infrastructure.

For stakeholders across the ecosystem—pharmaceuticals, companies, healthcare providers and policymakers—the opportunity lies in building systems that ensure availability translates into accessibility, and accessibility into outcomes.

The Way Forward: Aligning Innovation with Access
The future of rare disease management in India will not be defined solely by scientific breakthroughs, but by how effectively those breakthroughs are delivered into clinical practice.

In WD, improving access to well-tolerated chelation therapies such as Trientine represents a tangible step towards better patient outcomes. More broadly, it signals a shift towards a healthcare model that prioritises continuity, accessibility and patient-centric care.

As the ecosystem continues to mature, the focus must remain clear: ensuring that no patient is limited not by the absence of treatment, but by the inability to access it.